Patents Assigned to International Vaccines Institute
-
Patent number: 10426826Abstract: The present invention relates to a Shigella strain, of which the surface exposure of a protective antigen existing on a cellular membrane is increased due to the destruction of a wzy gene of Shigella sp., and to a vaccine composition for treating or preventing shigellosis, containing the mutant Shigella strain as an active ingredient. The Shigella strain of the present invention has a cell wall with a reduced thickness since a gene encoding a protein necessary for polymerization of the O-saccharide antigen is deleted, and as a result, membrane antigens including protein antigens commonly existing in different Shigella spp. are more exposed to immune cells, and thus the Shigella strain can be favorably used as a vaccine composition for treating or preventing shigellosis, derived from various Shigella spp.Type: GrantFiled: April 22, 2016Date of Patent: October 1, 2019Assignee: International Vaccine InstituteInventors: Jae Ouk Kim, Min Jung Kim, Man Ki Song
-
Patent number: 9061001Abstract: Methods and compositions for enhancing an immune response to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites. The methods and compositions include host defense peptides, polyphosphazenes and immunostimulatory sequences to enhance the immune response to a coadministered antigen.Type: GrantFiled: October 15, 2009Date of Patent: June 23, 2015Assignees: University of Saskatchewan, Dalhousie University, International Vaccines Institute, University of British ColumbiaInventors: Sylvia van Drunen Littel-van den Hurk, Volker Gerdts, Andrew Potter, Lorne Babiuk, Robert Hancock, Scott Halperin, Jennifer Kovacs-Nolan, George Mutwiri, Song Lee, Mi-Na Kweon, Jason Kindrachuk, Melissa Elliott
-
Patent number: 9023363Abstract: The present invention relates to cholera toxin CTA1 protein fragments, adjuvant compositions, and methods relating to adjuvants for vaccines. The invention also relates to using recombinant CTA1 fragments conjugated to a polypeptide containing a protein transduction domain or cell-penetrating peptide as an immunomodulator.Type: GrantFiled: October 21, 2009Date of Patent: May 5, 2015Assignee: International Vaccine InstituteInventors: Cecil Czerkinsky, Manki Song
-
Publication number: 20140248313Abstract: Methods and compositions for enhancing an immune response to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites. The methods and compositions include host defense peptides, polyphosphazenes and immunostimulatory sequences to enhance the immune response to a coadministered antigen.Type: ApplicationFiled: February 15, 2013Publication date: September 4, 2014Applicants: University of Saskatchewan, International Vaccine Institute, Dalhousie University, The University of British ColumbiaInventors: University of Saskatchewan, The University of British Columbia, Dalhousie University, International Vaccine Institute
-
Publication number: 20140227312Abstract: The present invention relates to cholera toxin CTA1 protein fragments, adjuvant compositions, and methods relating to adjuvants for vaccines. The invention also relates to using recombinant CTA1 fragments conjugated to a polypeptide containing a protein transduction domain or cell-penetrating peptide as an immunomodulator.Type: ApplicationFiled: October 21, 2009Publication date: August 14, 2014Applicant: INTERNATIONAL VACCINE INSTITUTEInventors: Cecil Czerkinsky, Manki Song
-
Patent number: 8168203Abstract: The present invention relates to protein antigens IcsP2 and SigA2 from Shigella that are common among numerous Shigella types and species and which can protect against shigellosis or other enteric infections when administered as vaccines. In addition, the present invention relates to antigens that are in common between Shigella species and enteroinvasive Escherichia coli (EIEC). The invention also relates to the use of antibodies raised against these antigens and of DNA probes for use in the diagnosis of Shigella and EIEC infections.Type: GrantFiled: January 22, 2010Date of Patent: May 1, 2012Assignee: International Vaccine InstituteInventors: Cecil Czerkinsky, Dong Wook Kim
-
Patent number: 8147847Abstract: The present invention relates to protein antigens IcsP2 and SigA2 from Shigella that are common among numerous Shigella types and species and which can protect against shigellosis or other enteric infections when administered as vaccines. In addition, the present invention relates to antigens that are in common between Shigella species and enteroinvasive Escherichia coli (EIEC). The invention also relates to the use of antibodies raised against these antigens and of DNA probes for use in the diagnosis of Shigella and EIEC infections.Type: GrantFiled: October 21, 2009Date of Patent: April 3, 2012Assignee: International Vaccine InstituteInventors: Cecil Czerkinsky, Dong Wook Kim
-
Publication number: 20100136045Abstract: The present invention relates to protein antigens IcsP2 and SigA2 from Shigella that are common among numerous Shigella types and species and which can protect against shigellosis or other enteric infections when administered as vaccines. In addition, the present invention relates to antigens that are in common between Shigella species and enteroinvasive Escherichia coli (EIEC). The invention also relates to the use of antibodies raised against these antigens and of DNA probes for use in the diagnosis of Shigella and EIEC infections.Type: ApplicationFiled: January 22, 2010Publication date: June 3, 2010Applicant: INTERNATIONAL VACCINE INSTITUTEInventors: CECIL CZERKINSKY, DONG WOOK KIM